Overview

Cryoablation Combined With Sintilimab Plus Lenvatinib In Previously Treated Unresectable Liver Metastasis From Solid Tumors

Status:
Recruiting

Trial end date:
2024-10-30

Target enrollment:

Participant gender:

Summary

The objective of this study is to evaluate the efficacy and safety of cryoablation combined with Sintilimab plus lenvatinib for patients with unresectable liver metastasis, who had progressed after, or were refractory to first- or later-line therapy.

Phase:

Phase 2

Details

Lead Sponsor:

Fudan University

Treatments:

Lenvatinib